Dr Edmund O'Flaherty, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Edmund O'Flaherty shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.

Dr Deanna Windham, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Deanna Windham shares her Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.

Dr David Borenstein, LDN Radio Show 28 Dec 2016 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: Today we are joined by Dr. David Bornstein.  Thank you for joining us, David. 

Dr David Borenstein: Thank you for having me. 

Dr Brian Udell on Low Dose Naltrexone, LDN Radio Show 17 May 2017 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Today our guest would be Dr. Brian Udell who is the medical director of the Child Development Center of America in Florida.

Linda Elsegood: Thank you for joining us today Dr. Brian Udell!

Becca - England: Crohn's Disease (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

I would like to introduce Becca from England who takes LDN for Crohn's disease.

Thank you for joining me, Becca.

Becca: Hello Linda.

Low-Dose Naltrexone for Fibromyalgia and ME/CFS

Verywell Health
04 November 2020
https://www.verywellhealth.com/low-dose-naltrexone-ldn-for-fibromyalgia-cfs-716070

Low-dose naltrexone: tricking the body to heal itself

Exp Biol Med (Maywood)
September 2011
https://www.sciencedaily.com/releases/2011/09/110902133047.htm

Low-Dose Naltrexone (LDN) Treatment for Crohn's Disease (CD): A Tertiary Care Center Experience

Am J Gastroenterol
October 2011
https://journals.lww.com/ajg/Fulltext/2011/10002/Low_Dose_Naltrexone__LDN__Treatment_for_Crohn_s.1223.aspx

Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study

J Clin Gastroenterol
01 April 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586944/

Background
There is an unmet need for safe and effective medicines to treat children with Crohn’s disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells.

Apparent efficacy and safety of low dose naltrexone in Australian patients with active Crohn's disease

J Gastroenterology and Hepatology
October 2013
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.12365_6

Open label and randomised controlled trial evidence indicates that low dose naltrexone (LDN), a strong opioid antagonist, has efficacy in reducing inflammatory activity in patients with Crohn’s disease. All evidence has come from one institution.